Advertisement

Gene Therapy for Pancreatic Cancer

  • Nicholas R. Lemoine

Abstract

There are a number of compelling reasons why cancer of the pancreas may be a particularly good model for the development of gene therapy strategies. First, the genetic basis of pancreatic cancer is becoming very well characterized because of intense activity in laboratories around the world (reviewed in refs. 1 and 2), and each oncogene and tumor-suppressor gene identified represents a novel target for genetic therapy (3). Second, the recognition that there may be familial inherited predisposition to pancreatic cancer, either alone (4) or in association with other malignancies such as melanoma (5, 6, 7), offers the possibility of prevention by genetic intervention. Third, because of the poor response to conventional treatment and dismal prognosis of the disease, patients and clinicians are willing to explore such new therapies. This chapter reviews the latest possibilities for exploiting genetic technology in the treatment and prevention of pancreatic cancer, and highlights the most promising areas for clinical application.

Keywords

Pancreatic Cancer Gene Therapy Gene Transfer Cystic Fibrosis Transmembrane Conductance Regulator Human Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lemoine NR. Molecular pathology of pancreatic duct neoplasms. In: Sirica A and Long-necker DS (eds), Biliary and pancreatic ductal epithelium: pathobiology and pathophysiology. Marcel Dekker, New York, 1996; pp. 502–525.Google Scholar
  2. 2.
    McCormick CSF and Lemoine NR. Molecular biology: diagnostic and therapeutic potentials. In: Howard JM (ed), Surgical diseases of the pancreas. Williams and Wilkins, Media, PA 1996; pp. 439–448.Google Scholar
  3. 3.
    Lemoine NR. Genetic intervention for the treatment and prevention of pancreatic cancer. Dig Surg 1995; 11:170–177.CrossRefGoogle Scholar
  4. 4.
    Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23:251–275.PubMedGoogle Scholar
  5. 5.
    Lynch HT and Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991; 6:127–131.PubMedCrossRefGoogle Scholar
  6. 6.
    Whelan AJ, Bartsch D, and Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333:975–977.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970–974.PubMedCrossRefGoogle Scholar
  8. 8.
    Bilimoria MM, and Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995; 45:263–278.PubMedCrossRefGoogle Scholar
  9. 9.
    Gullick WJ, and Handyside AH. Pre-implantation diagnosis of inherited predisposition to cancer. Eur J Cancer 1994; 13:2030–2032.CrossRefGoogle Scholar
  10. 10.
    Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genet 1996; 14:141–145.PubMedCrossRefGoogle Scholar
  11. 11.
    Kattwinkel J, Lapey A, Di Sant’Agnese PA, and Edwards WA. Hereditary pancreatitis: three new kindreds and a critical review of the literature. Pediatrics 1973; 51:55–69.PubMedGoogle Scholar
  12. 12.
    Friend SH. Breast cancer susceptibility testing: realities in the post-genomic era. Nature Genet 1996; 13:16–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Goggins M, Schutte M, Lu L, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360–5364.PubMedGoogle Scholar
  14. 14.
    Hengge UR, Chan EF, Foster RA, Walker PS, and Vogel JC. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nature Genet 1995; 10:161–166.PubMedCrossRefGoogle Scholar
  15. 15.
    Gunzburg WH and Salmons B. Retroviral vectors. In: Lemoine NR and Cooper DN, (eds), Gene Therapy, Bios, Oxford, 1996; pp. 33–60.Google Scholar
  16. 16.
    Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retro viral gene transduction. N Engl J Med 1990; 323:570–578.PubMedCrossRefGoogle Scholar
  17. 17.
    Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, and Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256:1550–1552.PubMedCrossRefGoogle Scholar
  18. 18.
    Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, and Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4:39–69.PubMedCrossRefGoogle Scholar
  19. 19.
    Culver KW, Van Gilder J, Link CJ, Carlstrom T, Buroker T, Yuh W, et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 1994; 5:343–379.PubMedCrossRefGoogle Scholar
  20. 20.
    Russell SJ and Miller AD. Foamy virus vectors. J Virol 1996; 70:217–222.PubMedGoogle Scholar
  21. 21.
    Cosset FL, Takeuchi Y, Battini JL, Weiss RA, and Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69:7430–7436.PubMedGoogle Scholar
  22. 22.
    Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien DM, et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995; 32:1183–1195.PubMedCrossRefGoogle Scholar
  23. 23.
    Rother RP, Squinto SP, Mason JM, and Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995; 6:429–435.PubMedCrossRefGoogle Scholar
  24. 24.
    Ring CJA. Adenovirus vectors. In: Lemoine NR and Cooper DN (eds), Gene Therapy, Bios, Oxford, 1996; pp. 61–76.Google Scholar
  25. 25.
    Crystal RG, Jaffe A, Brody S, Mastrangeli A, McElvaney NG, Rosenfeld M, et al. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther 1995; 6:643–666.PubMedCrossRefGoogle Scholar
  26. 26.
    Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 1994; 8:42–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Brody SL, Metzger M, Danel C, Rosenfeld MA, and Crystal RG. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994; 5:821–836.PubMedCrossRefGoogle Scholar
  28. 28.
    Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, and Trapnell BC. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994; 5:731–744.PubMedCrossRefGoogle Scholar
  29. 29.
    Kochanek S, Clemens PR, Mitani K, Chen H-H, Chan S, and Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93:5731–5736.PubMedCrossRefGoogle Scholar
  30. 30.
    Bartlett JS, and Samulski RJ. Adeno-associated virus vectors for human gene therapy. In: Lemoine NR and Cooper DN (eds), Gene Therapy, Bios, Oxford, 1996; pp. 77–92.Google Scholar
  31. 31.
    Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, and Feigner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465–1468.PubMedCrossRefGoogle Scholar
  32. 32.
    Danko I and Wolff JA. Direct gene transfer into muscle. Vaccine 1994; 12:1499–1502.PubMedCrossRefGoogle Scholar
  33. 33.
    Davis HL, Whalen RG, and Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993; 4:151–159.PubMedCrossRefGoogle Scholar
  34. 34.
    Mahato RI, Kawabata K, Nomura T, Takakura Y, and Hashida M. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci 1995; 84:1267–1271.PubMedCrossRefGoogle Scholar
  35. 35.
    Mahato RI, Kawabata K, Takakura Y, and Hashida M. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995; 3:149–157.PubMedCrossRefGoogle Scholar
  36. 36.
    Jiao S, Williams P, Berg RK, Hodgeman BA, Liu L, Repetto G, and Wolff JA. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992; 3:21–33.PubMedCrossRefGoogle Scholar
  37. 37.
    Scheule RK and Cheng SH. Liposome delivery systems. In: Lemoine NR and Cooper DN, (eds), Gene Therapy, Bios, Oxford, 1996; pp. 93–112.Google Scholar
  38. 38.
    Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, et al. Liposomemediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995; 1:39–46.PubMedCrossRefGoogle Scholar
  39. 39.
    Caplen NJ, Gao X, Hayes P, Elaswarapu R, Fisher G, Kinrade E, et al. Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Gene Ther 1994; 1:139–147.PubMedGoogle Scholar
  40. 40.
    Nabel EG, Yang Z, Muller D, Chang AE, Gao X, Huang L, Cho KJ, and Nabel GJ. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 1994; 5:1089–1094.PubMedCrossRefGoogle Scholar
  41. 41.
    Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90:11, 307–11, 311.Google Scholar
  42. 42.
    Trubetskoy VS, Torchilin VP, Kennel SJ, and Huang L. Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells. Bioconjug Chem 1992; 3:323–327.PubMedCrossRefGoogle Scholar
  43. 43.
    Trubetskoy VS, Torchilin VP, Kennel S, and Huang L. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells. Biochim Biophys Acta 1992; 1131:311–313.PubMedCrossRefGoogle Scholar
  44. 44.
    Remy JS, Kichler A, Mordvinov V, Schuber F, and Behr JP. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses. Proc Natl Acad Sci USA 1995; 92:1744–1748.PubMedCrossRefGoogle Scholar
  45. 45.
    Cristiano RJ, Smith LC, Kay MA, Brinkley BR, and Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90:11, 548–11, 552.Google Scholar
  46. 46.
    Cristiano RJ, Smith LC, and Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA 1993; 90:2122–2126.PubMedCrossRefGoogle Scholar
  47. 47.
    Gao L, Wagner E, Cotten M, Agarwal S, Harris C, Romer M, et al. Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther 1993; 4:17–24.PubMedCrossRefGoogle Scholar
  48. 48.
    Curiel DT, Agarwal S, Wagner E, and Cotten M. Adenovirus enhancement of transferrinpolylysine-mediated gene delivery. Proc Natl Acad Sci USA 1991; 88: 8850–8854.PubMedCrossRefGoogle Scholar
  49. 49.
    Wu GY, Zhan P, Sze LL, Rosenberg AR, and Wu CH. Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. J Biol Chem 1994; 269:11, 542–11, 546.Google Scholar
  50. 50.
    Cheng L, Ziegelhoffer PR, and Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90:4455–4459.PubMedCrossRefGoogle Scholar
  51. 51.
    Yang NS, Burkholder J, Roberts B, Martinell B, and McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990; 87:9568–9572.PubMedCrossRefGoogle Scholar
  52. 52.
    Jiao S, Cheng L, Wolff JA, and Yang NS. Particle bombardment-mediated gene transfer and expression in rat brain tissues. Biotechnol NY 1993; 11:497–502.CrossRefGoogle Scholar
  53. 53.
    Yang NS and Sun WH. Gene gun and other non-viral approaches for cancer gene therapy. Nature Med 1995; 1:481–483.PubMedCrossRefGoogle Scholar
  54. 54.
    Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 1995; 92:2889–2893.PubMedCrossRefGoogle Scholar
  55. 55.
    Nellen W and Lichtenstein C. What makes an mRNA anti-sense-itive? Trends Biochem Sci 1993; 18:419–423.PubMedCrossRefGoogle Scholar
  56. 56.
    Carter G and Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer 1993; 67:869–876.PubMedCrossRefGoogle Scholar
  57. 57.
    Barton CM and Lemoine NR. Antisense oligonucleotides directed against TP53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71:429–437.PubMedCrossRefGoogle Scholar
  58. 58.
    Bielinska A, Shivdasani RA, Zhang LQ, and Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250:997–1000.PubMedCrossRefGoogle Scholar
  59. 59.
    Sullenger B A, Gallardo HF, Ungers GE, and Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63:601–608.PubMedCrossRefGoogle Scholar
  60. 60.
    Sullenger BA, Gallardo HF, Ungers GE, and Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991; 65:6811–6816.Google Scholar
  61. 61.
    Porter A. Gene targeting as an approach to gene therapy. In: Lemoine NR and Cooper DN, (eds), Gene Therapy, Bios, Oxford, 1996; pp. 169–190.Google Scholar
  62. 62.
    Jones PH, Harper S, and Watt FM. Stem cell patterning and fate in human epidermis. Cell 1995; 80:83–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppel G, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64:1076–1082.PubMedCrossRefGoogle Scholar
  64. 64.
    Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, and Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142:1534–1543.PubMedGoogle Scholar
  65. 65.
    Simon B, Weinel R, Hohne M, Watz J, Schmidt J, Kortner G, and Arnold R. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic cancer. Gastroenterology 1994; 106:1645–1651.PubMedGoogle Scholar
  66. 66.
    Ruggeri BA, Klein-Szanto AJP, Huang LY, and Lang D. P53 and RB-1 tumor suppressor gene expression and alterations in human pancreatic cancer. Int J Pancreatol 1994; 16:193–196.Google Scholar
  67. 67.
    Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and KRAS alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8:289–298.PubMedGoogle Scholar
  68. 68.
    Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, and Kern SE. p53 mutations in pancreatic carcinoma and evidence of common homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025–3033.PubMedGoogle Scholar
  69. 69.
    Berrozpe G, Schaeffer J, Peinado MA, Real FX, and Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreas cancer. Int J Cancer 1994; 58:185–191.PubMedCrossRefGoogle Scholar
  70. 70.
    Chen PL, Chen YM, Bookstein R, and Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250:1576–1580.PubMedCrossRefGoogle Scholar
  71. 71.
    Frebourg T, Sadelain M, Ng YS, Kassel J, and Friend SH. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 1994; 54:878–881.PubMedGoogle Scholar
  72. 72.
    Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, and Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model [see comments]. J Natl Cancer Inst 1994; 86:1458–1462.PubMedCrossRefGoogle Scholar
  73. 73.
    Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5:1079–1088.PubMedCrossRefGoogle Scholar
  74. 74.
    Zhang WW, Fang X, Mazur W, French BA, Georges RN, and Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1:5–13.PubMedGoogle Scholar
  75. 75.
    Zhang WW and Roth JA. Anti-oncogene and tumor suppressor gene therapy—examples from a lung cancer animal model. In Vivo 1994; 8:755–769.PubMedGoogle Scholar
  76. 76.
    Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, and Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54:3662–3667.PubMedGoogle Scholar
  77. 77.
    Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, and Shillitoe EJ. Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995; 2:105–111.PubMedGoogle Scholar
  78. 78.
    Clayman GL, el Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, and Liu TJ. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55:1–6.PubMedGoogle Scholar
  79. 79.
    Liu TJ, el Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, and Clayman GL. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55:3117–3122.PubMedGoogle Scholar
  80. 80.
    Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, and Goepfert H. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg 1996; 722:489–493.CrossRefGoogle Scholar
  81. 81.
    Yang C, Cirielli C, Capogrossi MC, and Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55:4210–4213.PubMedGoogle Scholar
  82. 82.
    Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55:5151–5155.PubMedGoogle Scholar
  83. 83.
    Bookstein R, Demers W, Gregory R, Maneval D, Park J, and Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 1996; 23:66–77.PubMedGoogle Scholar
  84. 84.
    Werthman PE, Drazan KE, Rosenthal JT, Khalili R, and Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996; 155:753–756.PubMedCrossRefGoogle Scholar
  85. 85.
    Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, and Mitchell MF. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56:3047–3054.PubMedGoogle Scholar
  86. 86.
    Drazan KE, Shen XD, Csete ME, Zhang WW, Roth JA, Busuttil RW, and Shaked A. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery 1994; 166:197–203.Google Scholar
  87. 87.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub LB, and Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54:2287–2291.PubMedGoogle Scholar
  88. 88.
    Harper J, Adami G, Wei N, Keyormarsi K, and Elledge S. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805–816.PubMedCrossRefGoogle Scholar
  89. 89.
    El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817–825.PubMedCrossRefGoogle Scholar
  90. 90.
    Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8:27–31.PubMedCrossRefGoogle Scholar
  91. 91.
    Liu Q, Yan Y-X, McClure M, Nakagawa H, Fujimura F, and Rustgi AK. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 1995; 10:619–622.PubMedGoogle Scholar
  92. 92.
    Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, and Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes, Chromosomes Cancer 1995; 14:189–195.PubMedCrossRefGoogle Scholar
  93. 93.
    Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, and Schmiegel W. Frequent codeletion of pl6/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996; 110:1215–1224.PubMedCrossRefGoogle Scholar
  94. 94.
    Mukhopadhyay T, Tainsky M, Cavender AC, and Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51:1744–1748.PubMedGoogle Scholar
  95. 95.
    Georges RN, Mukhopadhyay T, Zhang Y, Yen N, and Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993; 53:1743–1746.PubMedGoogle Scholar
  96. 96.
    Yoshida T and Aoki K. Gene therapy for pancreatic cancer. Tanpakushitsu Kakusan Koso 1995; 40:2727–2731.PubMedGoogle Scholar
  97. 97.
    Aoki K, Yoshida T, Sugimura T, and Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55:3810–3816.PubMedGoogle Scholar
  98. 98.
    Bayever E and Iversen P. Oligonucleotides in the treatment of leukemia. Hematol Oncol 1994; 12:9–14.PubMedCrossRefGoogle Scholar
  99. 99.
    Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, et al. Phase I trial of an antisense oligonucleotide OL(l)p53 in hematologic malignancies. J Clin Oncol, 1996; 14:1320–1326.PubMedGoogle Scholar
  100. 100.
    Cai DW, Mukhopadhyay T, and Roth JA. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 1995; 2:199–205.PubMedGoogle Scholar
  101. 101.
    Colomer R, Lupu R, Bacus SS, and Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994; 70:819–825.PubMedCrossRefGoogle Scholar
  102. 102.
    Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, and Lemoine NR. The cerbB-2 proto-oncogene in human pancreatic cancer. J Pathol 1990; 161:195–200.PubMedCrossRefGoogle Scholar
  103. 103.
    Ebbinghaus SW, Gee JE, Rodu B, Mayfield CA, Sanders G, and Miller DM. Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 1993; 92:2433–2439.PubMedCrossRefGoogle Scholar
  104. 104.
    Kitada S, Takayama S, De Riel K, Tanaka S, and Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994; 4:71–79.PubMedGoogle Scholar
  105. 105.
    Gao WY, Han FS, Storm C, Egan W, and Cheng YC. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992; 41:223–229.PubMedGoogle Scholar
  106. 106.
    Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92:4051–4055.PubMedCrossRefGoogle Scholar
  107. 107.
    Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, and Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270:2620–2627.PubMedCrossRefGoogle Scholar
  108. 108.
    Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol 1995; 15:284–292.PubMedCrossRefGoogle Scholar
  109. 109.
    Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546–549.Google Scholar
  110. 110.
    Yamamoto T, Yamamoto S, Kataoka T, and Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 1994; 4:119–122.PubMedGoogle Scholar
  111. 111.
    Yamamoto T, Yamamoto S, Kataoka T, and Tokunaga T. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol 1994; 38:831–836.PubMedGoogle Scholar
  112. 112.
    Harris JD and Lemoine NR. Strategies for targeted gene therapy. Trends Genet 1996; 12:400–405.PubMedCrossRefGoogle Scholar
  113. 113.
    Moolten FL. Gene therapy: creating mosaic pattern of drug susceptibility. Mt Sinai J Med 1986; 53:232.PubMedGoogle Scholar
  114. 114.
    Schnierle BS and Groner B. Retroviral targeted delivery. Gene Ther 1996; 3:1069–1073.PubMedGoogle Scholar
  115. 115.
    Schnierle BS, Moritz D, Jeschke M, and Groner B. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther 1996; 3:334–342.PubMedGoogle Scholar
  116. 116.
    Han X, Kasahara N, and Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92:9747–9751.PubMedCrossRefGoogle Scholar
  117. 117.
    Huber BE, Richards CA, and Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88:8039–8043.PubMedCrossRefGoogle Scholar
  118. 118.
    Richards CA and Huber BE. Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum Gene Ther 1993; 4:143–150.PubMedCrossRefGoogle Scholar
  119. 119.
    Harris JD, Gutierrez AA, Hurst HC, Sikora K, and Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994; 1:170–175.PubMedGoogle Scholar
  120. 120.
    Sikora K, Harris J, Hurst H, and Lemoine N. Therapeutic strategies using c-erbB-2 promoter-controlled drug activation. Ann NY Acad Sci 1994; 716:115–124.PubMedCrossRefGoogle Scholar
  121. 121.
    Ring CJA, Harris JD, Hurst HC, and Lemoine NR. Suicide gene expression induced in tumour cells treated with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Therapy 1996; 3:1094–1103.PubMedGoogle Scholar
  122. 122.
    Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, and Kishimoto T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54:5258–5261.PubMedGoogle Scholar
  123. 123.
    Richards CA, Wolberg AS, and Huber BE. The transcriptional control region of the human carcinoembryonic antigen gene: DNA sequence and homology studies. DNA Seq 1993; 4:185–196.PubMedGoogle Scholar
  124. 124.
    DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, and Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116:205–213.PubMedGoogle Scholar
  125. 125.
    Manome Y, Abe M, Hagen MF, Fine HA, and Kufe DW. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 1994; 54:5408–13.PubMedGoogle Scholar
  126. 126.
    Ring CJA, Martin L-A, Blouin P, Hurst HC, and Lemoine NR. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumor-selective expression of a prodrug-activating enzyme. Gene Therapy 1997; 4:1045–1052.PubMedCrossRefGoogle Scholar
  127. 127.
    Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, and Abraham GN. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274–5283.PubMedGoogle Scholar
  128. 128.
    Vile RG, Nelson JA, Castleden S, Chong H, and Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HS Vtk gene involves an immune component. Cancer Res 1994; 54:6228–6234.PubMedGoogle Scholar
  129. 129.
    Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, et al. Expression of MHC class-i and class-II antigens in pancreatic adenocarcinomas. Tissue Antigens 1996; 48:301–311.PubMedCrossRefGoogle Scholar
  130. 130.
    Mazumder A and Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159:495–507.PubMedCrossRefGoogle Scholar
  131. 131.
    Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863–1874.PubMedGoogle Scholar
  132. 132.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, and White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474–484.PubMedCrossRefGoogle Scholar
  133. 133.
    Galea-Lauri J and Gaken J. Cancer gene therapy II: immunomodulatory strategies. In: Lemoine NR, and Cooper DN (eds), Gene Therapy Bios, Oxford, 1996; pp. 277–299.Google Scholar
  134. 134.
    Bubenik J, Zeuthen J, Bubenikova D, Simova J, and Jandlova T. Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets. Anticancer Res 1993; 13:1457–1460.PubMedGoogle Scholar
  135. 135.
    Cordier L, Duffour MT, Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M, and Haddada H. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 1995; 2:16–21.PubMedGoogle Scholar
  136. 136.
    Gilboa E, Lyerly HK, Vieweg J, and Saito S. Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 1994; 5:409–417.PubMedGoogle Scholar
  137. 137.
    Haddada H, Ragot T, Cordier L, Duffour MT, and Perricaudet M. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4:703–711.PubMedCrossRefGoogle Scholar
  138. 138.
    Hathorn RW, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C, de Kernion JB, and Belldegrun A. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha-gene transfer. Cancer 1994; 74:1904–1911.PubMedCrossRefGoogle Scholar
  139. 139.
    Hurford RK, Jr., Dranoff G, Mulligan RC, and Tepper RI, Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genet 1995; 10:430–435.PubMedCrossRefGoogle Scholar
  140. 140.
    Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 1993; 150:896–908.PubMedGoogle Scholar
  141. 141.
    Kim TS, Russell SJ, Collins MK, and Cohen EP. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 1992; 51:283–289.PubMedCrossRefGoogle Scholar
  142. 142.
    Krauss JC, Strome SE, Chang AE, and Shu S. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother Emphasis Tumor Immunol 1994; 16:77–84.PubMedCrossRefGoogle Scholar
  143. 143.
    Melani C, Chiodoni C, Arienti F, Maccalli C, Sule Suso J, Anichini A, Colombo MP, and Parmiani G. Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. Nat Immun 1994; 13:76–84.PubMedGoogle Scholar
  144. 144.
    Musiani P, Modesti A, Brunetti M, Modica A, Vitullo P, Gulino A, et al. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes. Nat Immun 1994; 13: 93–101.PubMedGoogle Scholar
  145. 145.
    Ohira T, Ohe Y, Heike Y, Podack ER, Olsen KJ, Nishio K, et al. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected sub-line. Gene Ther 1994; 1:269–275.PubMedGoogle Scholar
  146. 146.
    Patel PM, Flemming CL, Russell SJ, McKay IA, MacLennan KA, Box GM, Eccles SA, and Collins MK. Comparison of the potential therapeutic effects of interleukin 2 or inter-leukin 4 secretion by a single tumour. Br J Cancer 1993; 68:295–302.PubMedCrossRefGoogle Scholar
  147. 147.
    Porgador A, Tzehoval E, Vadai E, Feldman M, and Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, inter-leukin-6, or interferon-gamma genes. J Immunother 1993; 14:191–201.CrossRefGoogle Scholar
  148. 148.
    Roth C, Mir L, Cressent M, Quintin Colonna F, Ley V, Fradelizi D, and Kourilsky P. IL-2 gene transduction in malignant cells: applications in cancer containment. Bone Marrow Transplant 1992; 1:174–175.Google Scholar
  149. 149.
    Russell SJ, Eccles SA, Flemming CL, Johnson CA, and Collins MK. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47:244–251.PubMedCrossRefGoogle Scholar
  150. 150.
    Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, and Fakhrai H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother Emphasis Tumor Immunol 1995; 17:201–208.PubMedCrossRefGoogle Scholar
  151. 151.
    Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995; 55:1902–1910.PubMedGoogle Scholar
  152. 152.
    Rosenthal FM, Cronin K, Bannerji R, Golde DW, and Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 1994; 83:1289–1298.PubMedGoogle Scholar
  153. 153.
    Rosenthal FM, Fruh R, Henschler R, Veelken H, Kulmburg P, Mackensen A, et al. Cytokine therapy with gene-transfected cells: single injection of irradiated granulocytemacrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice. Blood 1994; 84:2960–2965.PubMedGoogle Scholar
  154. 154.
    Wiltrout RH, Gregorio TA, Fenton RG, Longo DL, Ghosh P, Murphy WJ, and Komschlies KL. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol 1995; 22:9–16.PubMedGoogle Scholar
  155. 155.
    Munger W, DeJoy SQ, Jeyaseelan R, Sr., Torley LW, Grabstein KH, Eisenmann J, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T-cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165:289–293.PubMedCrossRefGoogle Scholar
  156. 156.
    Gamero AM, Ussery D, Reintgen DS, Puleo CA, and Djeu JY. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD 18-dependent, perforin-related mechanism. Cancer Res 1995; 55:4988–4994.PubMedGoogle Scholar
  157. 157.
    Lewko WM, Smith TL, Bowman DJ, Good RW, and Oldham RK. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother 1995; 10:13–20.PubMedCrossRefGoogle Scholar
  158. 158.
    Clary BM, Coveney EC, Blazer DGr, Philip R, and Lyerly HK. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery 1996; 120:174–181.PubMedCrossRefGoogle Scholar
  159. 159.
    Townsend SE, Su FW, Atherton JM, and Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54:6477–6483.PubMedGoogle Scholar
  160. 160.
    Townsend SE and Allison JP. Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells. Science 1993; 259:368–370.PubMedCrossRefGoogle Scholar
  161. 161.
    Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, and Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71:1093–1102.PubMedCrossRefGoogle Scholar
  162. 162.
    Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, and Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T-cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996; 156:1126–1131.Google Scholar
  163. 163.
    Yang G, Hellstrom KE, Hellstrom I, and Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154:2794–2800.PubMedGoogle Scholar
  164. 164.
    Hodge JW, Abrams S, Schlom J, and Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552–5555.Google Scholar
  165. 165.
    Dohring C, Angman L, Spagnoli G, and Lanzavecchia A. T-helper-and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994; 57:754–759.PubMedCrossRefGoogle Scholar
  166. 166.
    Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, and Eberlein TJ. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995; 155:4486–4491.PubMedGoogle Scholar
  167. 167.
    Conry RM, LoBuglio AF, Kantor J, Schlom J, Loechel F, Moore SE, et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54:1164–1168.PubMedGoogle Scholar
  168. 168.
    Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, and Curiel DT. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995; 2:59–65.PubMedGoogle Scholar
  169. 169.
    Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Pike J, and Curiel DT. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995; 2:33–38.PubMedGoogle Scholar
  170. 170.
    McLaughlin JP, Schlom J, Kantor JA, and Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996; 56:2361–2367.PubMedGoogle Scholar
  171. 171.
    Gedde Dahl Td, Fossum B, Eriksen JA, Thorsby E, and Gaudernack G. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 1993; 23:754–760.PubMedCrossRefGoogle Scholar
  172. 172.
    Fossum B, Olsen AC, Thorsby E, and Gaudernack G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21 ras-derived peptide (13Gly→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995; 40:165–172.PubMedGoogle Scholar
  173. 173.
    Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, et al. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 1995; 55:2984–2987.PubMedGoogle Scholar
  174. 174.
    Jung S and Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173:273–276.PubMedCrossRefGoogle Scholar
  175. 175.
    Gedde Dahl Td, Eriksen JA, Thorsby E, and Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 1992; 33:266–274.PubMedCrossRefGoogle Scholar
  176. 176.
    Fossum B, Gedde Dahl Td, Hansen T, Eriksen JA, Thorsby E, and Gaudernack G. Overlapping epitopes encompassing a point mutation (12 Gly→Arg) in p21 ras can be recognized by HLA-DR,-DP and-DQ restricted T cells. Eur J Immunol 1993; 23:2687–2691.PubMedCrossRefGoogle Scholar
  177. 177.
    Fossum B, Breivik J, Meling GI, Gedde Dahl Tr, Hansen T, Knutsen I, et al. A K-ras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T-cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer 1994; 58:506–511.Google Scholar
  178. 178.
    Fenton RG, Keller CJ, Hanna N, and Taub DD. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst 1995; 87:1853–1861.PubMedCrossRefGoogle Scholar
  179. 179.
    Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde Dahl Tr, Stokke KT, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996; 65:450–453.PubMedCrossRefGoogle Scholar
  180. 180.
    Rudy W, Hofmann M, Schwartz AR, Zoller M, Heider KH, Ponta H, and Herrlich P. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993; 53:1262–1268.PubMedGoogle Scholar
  181. 181.
    Castella EM, Ariza A, Ojanguren I, Mate JL, Roca X, Fernandezvasalo A, and Navaspalacios JJ. Differential expression of CD44v6 in adenocarcinoma of the pancreas—an immunohistochemical study. Virchows Arch 1996; 429:191–195.PubMedCrossRefGoogle Scholar
  182. 182.
    Hekele A, Dall P, Moritz D, Wels W, Groner B, Herrlich P, and Ponta H. Growth retardation of tumors by adoptive transfer of cytotoxic T-lymphocytes reprogrammed by CD44v6-specific scfv-zeta-chimera. Int J Cancer 1996; 68:232–238.PubMedCrossRefGoogle Scholar
  183. 183.
    Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, et al. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997; 385:78–80.PubMedCrossRefGoogle Scholar
  184. 184.
    Ojeifo JO, Forough R, Paik S, Maciag T, and Zwiebel JA. Angiogenesis-directed implantation of genetically modified endothelial cells in mice. Cancer Res 1995; 55:2240–2244.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Nicholas R. Lemoine

There are no affiliations available

Personalised recommendations